Riluzole

Riluzole
Clinical data
Trade names	Rilutek, Tiglutik, Exservan, others
AHFS/Drugs.com	Monograph
MedlinePlus	a696013
License data	EU EMA: by INN; US FDA: Riluzole;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	N07XX02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx Only;
Pharmacokinetic data
Bioavailability	60±18%
Protein binding	97%
Metabolism	Hepatic (CYP1A2)
Elimination half-life	9–15 hours
Excretion	Urine (90%)
Identifiers
	IUPAC name 6-(trifluoromethoxy)benzothiazol-2-amine;
CAS Number	1744-22-5 ;
PubChem CID	5070;
IUPHAR/BPS	2326;
DrugBank	DB00740 ;
ChemSpider	4892 ;
UNII	7LJ087RS6F;
KEGG	D00775 ;
ChEMBL	ChEMBL744 ;
CompTox Dashboard (EPA)	DTXSID3045192 ;
ECHA InfoCard	100.124.754
Chemical and physical data
Formula	C8H5F3N2OS
Molar mass	234.20 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)Oc1ccc2nc(sc2c1)N;
	InChI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13) ; Key:FTALBRSUTCGOEG-UHFFFAOYSA-N ;
	(verify)

Riluzole is a medication used to treat amyotrophic lateral sclerosis and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months. Riluzole is available in tablet and liquid form.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.